Johnson & Johnson Remicade — Percent Change (as a percent) decreased by 62.6% to 16.6% in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 130.2%, from -54.9% to 16.6%. This decline may warrant attention — for this metric, higher values are generally preferred.
A positive percentage indicates growth or resilience, whereas a negative percentage highlights accelerating revenue decline and the impact of market competition.
This metric measures the period-over-period percentage growth or decline in net sales for the Remicade product line. It...
Comparable to year-over-year or sequential growth rate metrics for individual pharmaceutical products or therapeutic franchises across the industry.
jnj_segment_remicade_percent_change_as_a_percent| Q2 '21 | Q3 '21 | Q4 '21 | Q2 '22 | Q3 '22 | Q4 '22 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -101% | -21.8% | -69.7% | -3.6% | -124.8% | -98.3% | -122.5% | -60.4% | -64.7% | -40.3% | -54.9% | -37.3% | 44.4% | 16.6% |
| QoQ Change | — | +78.4% | -219.7% | +94.8% | <-999% | +21.2% | -24.6% | +50.7% | -7.1% | +37.7% | -36.2% | +32.1% | +219.0% | -62.6% |
| YoY Change | — | — | — | +96.4% | -472.5% | -41.0% | <-999% | +51.6% | — | +67.1% | +9.1% | +42.3% | +210.2% | +130.2% |
We use cookies for analytics. See our Privacy and Cookie Policy.